IP Library › Granted Patent US 12,324,789
Granted Patent B2
US 12,324,789 · App. 16/106,420 · Granted Jun 10, 2025

Method to treat psoriasis

Inventors: Lekhram Changoer (Ridderkerk, NL); George Anastassov (New York, NY)
Assignee: APIRx Pharmaceutical USA, LLC
A61K31/05A61K9/0014A61K31/352A61K47/12A61K47/36A61K47/46A61P17/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,324,789
App. No.
16/106,420
Granted
Jun 10, 2025
Kind
B2
Abstract

A method to treat the skin condition psoriasis is described in this invention. The method comprises topical application of a composition containing cannabinoids, in particular cannabidiol and cannabigerol at a concentration of 3%-20% by weight of the composition. The topical application is applied at least twice daily for six weeks.

Claims (10)

1. A method to treat psoriasis, the method comprising:

administering a topical composition containing cannabinoids onto skin areas affected by psoriasis of a subject in need thereof,

wherein the topical composition comprises cannabidiol (CBD) and cannabigerol (CBG) at a total weight percent of 15% of the composition,

wherein the topical composition comprises CBG and CBD in a weight ratio of 2:1 (CBG: CBD), and

wherein the topical composition is an ointment.

2. The method of claim 1 , wherein the cannabinoids in the composition are sourced naturally.

3. The method of claim 1 , wherein the cannabinoids in the composition are synthetic.

4. The method of claim 1 , wherein the cannabinoids in the composition are nanoencapsulated with particle sizes of 20 to 40 nanometers.

5. The method of claim 1 , wherein the composition further comprises-sodium oleyl hyaluronate.

6. The method of claim 1 , wherein the topical composition is applied twice daily per day for six weeks onto affected skin areas on a subject having psoriasis.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 26, 2020
From: AXIM BIOTECHNOLOGIES, INC.
To: APIRX PHARMACEUTICAL USA, LLC
Reel/Frame 052752/0519 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 7, 2018
From: CHANGOER, LEKHRAM; ANASTASSOV, GEORGE
To: AXIM BIOTECHNOLOGIES, INC.
Reel/Frame 046819/0704 →
Continuity (2)
Provisional Application 62550877 · Aug 28, 2017
Related Publication 20190060250A1 · Feb 28, 2019
References Cited (42)
US 8808734B2 · Winnicki · 2014 [cited by examiner]
US 20080255224A1 · Blum · 2008 [cited by examiner]
US 20160235661A1 · Changoer et al. · 2016 [cited by applicant]
US 20170112855A1 · Modi · 2017 [cited by examiner]
GB 2542797A · 2017 [cited by applicant]
WO WO2014082609A1 · 2014 [cited by examiner]
WO WO2016103254A1 · 2016 [cited by examiner]
WO WO2016209802A1 · 2016 [cited by applicant]
WO WO2017027553A1 · 2017 [cited by applicant]
Smejkalova et al. “Topical Drug Delivery by Hyaluronan Polymeric Micelles”. Front. Bioeng. Biotechnol. Conference Abstract: 10th World Biomaterials Congress. Published Online Mar. 30, 2016. (Year: 2016). [cited by examiner]
Kim, J.S., et al. “Cannabinoid receptors: Their impact in epidermal differentiation and possible role in treatment of psoriasis”, J. Am. Acad. Derm., AB 28, p. 1097, May 2015. [cited by applicant]
Wilkinson, J.D. et al. “Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis”, J. Derm. Sci. (2007) 45, 87-92. [cited by applicant]
Ando T, Xiao W, Gao P, Namiranian S, Matsumoto K, Tomimori Y, et al. Critical Role for Mast Cell Stat5 Activity in Skin Inflammation. Cell Reports. 6 (2):366-76. [cited by applicant]
Biro T, Toth B I, Hasko G, Paus R, Pacher P. The Endocannabinoid System of the Skin in Health and Disease: Novel Perspectives and Therapeutic Opportunities. Trends in Pharmacological Sciences. 2009; 30 (8):411-20. [cited by applicant]
Borrelli F, Pagano E, Romano B, Panzera S, Maiello F, Coppola D, et al. Colon Carcinogenesis is Inhibited by the TRPM8 Antagonist Cannabigerol, a Cannabis-Derived Non-Psychotropic Cannabinoid. Carcinogenesis. 2014; 35 (… [cited by applicant]
Brenneisen R, Egli A, Elsohly M A, Henn V, Spiess Y. The Effect of Orally and Rectally Administered Delta 9-Tetrahydrocannabinol on Spasticity: a Pilot Study With 2 Patients. International Journal of Clinical Pharmacolo… [cited by applicant]
Campos A C, Moreira F, Gomes F V, Del Bel E A, Guimarães F S. Multiple Mechanisms Involved in the Large-Spectrum Therapeutic Potential of Cannabidiol in Psychiatric Disorders. Philosophical Transactions of the Royal Soc… [cited by applicant]
Cascio M, Gauson L, Stevenson L, Ross R, Pertwee R. Evidence that the Plant Cannabinoid Cannabigerol is a Highly Potent A(2)-Adrenoceptor Agonist and Moderately Potent 5HT(1A) Receptor Antagonist. Br. J. Pharmacol. 2010… [cited by applicant]
Cuba L F, Salum F G, Cherubini K, Figueiredo M A. Cannabidiol: An Alternative Therapeutic Agent for Oral Mucositis? Journal of Clinical Pharmacy and Therapeutics. 2017. [cited by applicant]
Guttman-Yassky E, Krueger J G, Lebwohl M G. Systemic Immune Mechanisms in Atopic Dermatitis and Psoriasis with Implications for Treatment. Experimental Dermatology. 2017. [cited by applicant]
Jäger A, Dardalhon V, Sobel R A, Bettelli E, Kuchroo V K. Th1, Th17 and Th9 Effector Cells Induce Experimental Autoimmune Encephalomyelitis with Different Pathological Phenotypes. Journal of Immunology (Baltimore, Md.: … [cited by applicant]
Jastrza, et al, “The Origin and Biomedical Relevance of Cannabigerol” Int. J. Mol. Sci. 2022, 23, 7929. [cited by applicant]
McGilveray I J. Pharmacokinetics of Cannabinoids. Pain Research & Management. 2005; 10 Suppl A:15a-22a. [cited by applicant]
Mechoulam R, Peters M, Murillo-Rodriguez E, Hanuš L O. Cannabidiol—Recent Advances. Chemistry & Biodiversity. 2007; 4 (8):1678-92. [cited by applicant]
NIAMS. Questions and Answers about Psoriasis: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); 2016 [updated Jul. 2016. Available from: https://www.niams.nih.gov.health_info/psoriasis/#5. [cited by applicant]
Raphael I, Nalawade S, Eagar T N, Forsthuber T G. T Cell Subsets and Their Signature Cytokines in Autoimmune and Inflammatory Diseases. Cytokine. 2015; 74 (1):5-17. [cited by applicant]
Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermansson N, Leonova J, et al. The Orphan Receptor GPR55 is a Novel Cannabinoid Receptor. Br. J. Pharmacol. 2007; 152 (7):1092-101. [cited by applicant]
Small-Howard A L, Shimoda L M, Adra C N, Turner H. Anti-Inflammatory Potential of CB1-Mediated Camp Elevation in Mast Cells. The Biochemical Journal. 2005; 388 (Pt 2):465-73. [cited by applicant]
Toh M R, Teo V, Kwan Y H, Raaj S, Tan S Y, Tan J Z. Association Between Number of Doses Per Day, Number of Medications and Patient's Non-Compliance, and Frequency of Readmissions in a Multi-Ethnic Asian Population. Prev… [cited by applicant]
Turcotte C, Blanchet M R, Laviolette M, Flamand N. The CB2 Receptor and Its Role as a Regulator of Inflammation. Cellular and Molecular Life Sciences: CMLS. 2016; 73 (23):4449-70. [cited by applicant]
Valdeolivas S, Navarrete C, Cantarero I, Bellido M L, Munoz E, Sagredo O. Neuroprotective Properties of Cannabigerol in Huntington's Disease: Studies In R6/2 Mice and 3-Nitropropionate-Lesioned Mice. Neurotherapeutics: … [cited by applicant]
WHO. Global Report on Psoriasis. World Health Organisation; 2016. p. 49. [cited by applicant]
Cheng Y, Hitchcock S A., Targeting Cannabinoid Agonists for Inflammatory and Neuropathic Pain. Expert Opinion on Investigational Drugs. 2007; 16 (7):951-65. [cited by applicant]
Indhumathi et al., T Helper-2 Cytokine/Regulatory T-Cell Gene Polymorphisms and Their Relation With Risk of Psoriasis in a South Indian Tamil Cohort. Human immunology. 2017; 78 (2):209-15. [cited by applicant]
Iseger T A, Bossong M G., A Systematic Review of the Antipsychotic Properties of Cannabidiol in Humans. Schizophrenia Research. 2015; 162 (1-3):153-61. [cited by applicant]
Lambert D M, Fowler C J., The Endocannabinoid System: Drug Targets, Lead Compounds, and Potential Therapeutic Applications. J. of Medicinal Chemical. 2005; 48 (16):5059-87. [cited by applicant]
Maccarrone et al., Endocannabinoid Signaling at the Periphery: 50 Years After THC. Trends in Pharmacological Sciences. 2015; 36 (5):277-96. [cited by applicant]
Mashiko et al., Human Mast Cells Are Major II-22 Producers in Patients with Psoriasis and Atopic Dermatitis. The Journal of Allergy and Clinical Immunology. 2015; 136 (2):351-9.el. [cited by applicant]
Norooznezhad A H, Norooznezhad F., Cannabinoids: Possible Agents for Treatment of Psoriasis via Suppression of Angiogenesis and Inflammation. Med. Hypotheses. 2017; 99:15-8. [cited by applicant]
Russo E B et al., Agonistic Properties of Cannabidiol at 5-HT1a Receptors. Neurochemical Research. 2005; 30 (8):1037-43. [cited by applicant]
Sugawara et al., Endocannabinoids Limit Excessive Mast Cell Maturation and Activation in Human Skin. The Journal of Allergy and Clinical Immunology. 2012; 129 (3):726-38.e8. [cited by applicant]
Weiss L et al., Cannabidiol Lowers Incidence of Diabetes in Non-Obese Diabetic Mice. Autoimmunity. 2006; 39 (2): 143-51. [cited by applicant]